Posterior reversible encephalopathy syndrome (PRES) was first described in 15 patients by Hinchey et al. in 1996 . 1 The most common clinical symptoms and signs included headache, altered alertness and confusion, vomiting, seizures, and visual disturbance ranging from blurred vision to cortical blindness. Neuroimaging typically showed white matter edema in the posterior portions of the cerebral hemispheres, particularly in the parieto-occipital regions. The presumed etiologies for the 15 patients included hypertensive encephalopathy (n ¼ 4), preeclampsia (n ¼ 3), cyclosporine (n ¼ 4), tacrolimus (n ¼ 3), and interferon-a (n ¼ 1). With control of blood pressure and withdrawal or reduction of the immunosuppressive agent, all of the patients had resolution of symptoms within 2 weeks and neuroimaging normalized. Since the initial description of PRES, there have been a number of reports of its incidence following allogeneic bone marrow transplant in patients receiving cyclosporine or tacrolimus for graft-versus-host disease (GVHD) prophylaxis. [2] [3] [4] Toxic levels of the immunosuppressive medications do not appear to be required for the development of PRES. 5 In a previous report of a lung transplant recipient patient on sirolimus that developed a clinical syndrome similar to PRES, the neurotoxicity was attributed to dialysis disequilibrium syndrome. 6 The patient improved with adjustment in the dialysis regimen and continued on sirolimus without recurrent neurological complaints. An association between treatment with sirolimus and PRES has otherwise never been reported. Here we present a case of PRES occurring in the setting of treatment with sirolimus for GVHD prophylaxis.
A 39-year-old female with multiply relapsed mixed cellularity Hodgkin lymphoma underwent a non-myeloablative peripheral blood stem cell transplant from a unidirectional C-mismatched unrelated male donor (9/10 HLA match, mismatched in the direction of rejection) following conditioning with fludarabine, melphalan, and anti-thymocyte globulin. She received cyclosporine and mycophenolate mofetil for GVHD prophylaxis. Her posttransplant course was complicated by cyclosporine-related acute renal failure requiring hemodialysis. Her cyclosporine was therefore changed to sirolimus on day þ 19. In addition, her course was complicated by a skin rash most likely due to GVHD for which she received high dose steroids beginning day þ 37. On day þ 45, she presented with sudden onset bilateral loss of vision associated with a severe throbbing frontal headache, vomiting, and confusion. Her vital signs were significant for a blood pressure of 168/75 with a heart rate of 75. Initial evaluation revealed poor concentration with inability to perform serial sevens and impaired recent memory with recall of only one out of three items. Neurologic exam was remarkable for equal pupils that measured 6 mm and were responsive to light. Ophthalmologic exam revealed no papilledema and a small right retinal hemorrhage. Computerized tomography of the brain showed no abnormalities. Magnetic resonance imaging (MRI) showed abnormal FLAIR (fluid-attenuated inversion recovery) hyperintense signal changes involving the bilateral basal ganglia, bilateral parieto-occipital lobe cortices and subcortical white matter, periventricular white matter and bilateral cerebellar hemispheres (Figure 1a ). These abnormalities were not seen on the MRI performed 1 month before presentation and their distribution suggested PRES. The patient's sirolimus was discontinued and she was treated with labetalol that resulted in lowering her blood pressure to 130s-140s/70s within the first 12 hours after admission. On hospital day 1 the patient had mild improvement in vision with ability to see figures and shadows but inability to read. Her headache and confusion had resolved. On hospital day 2 the patient had complete recovery of her vision. The patient's sirolimus level 2 days before admission was 4.2 ng/ml and the levels on hospital days 1 and 2 were 1.3 and 1.4 ng/ml, respectively. She was discharged on mycophenolate mofetil and prednisone for GVHD treatment. A repeat MRI performed 1 month later showed almost complete resolution of the previous abnormalities (Figure 1b) . Although the only way to prove a direct causality between sirolimus and PRES in this patient would be to re-institute sirolimus in the setting of adequate blood pressure control, we decided that the risks would be too significant. It should be noted that this patient has had a history of labile hypertension since her transplant and, despite our best attempts to control it, has had documented blood pressure in the 150s/100 range without any neurological complaints both preceding and following the episode of PRES, further supporting the role of sirolimus as a causative agent in this episode.
Although PRES is usually reversible with prompt withdrawal or reduction of the immunosuppressive agent and blood pressure control, it can be associated with permanent neurologic deficits and death. 2 Early recognition and treatment is therefore warranted in patients presenting with the signs and symptoms associated with PRES. The differential diagnosis for this patients presenting symptoms of cortical blindness and confusion include stroke, cerebral sinus thrombosis, encephalitis, and demyelinating disorders. PRES can usually be distinguished from these other possible diagnoses by its characteristic MRI findings. 7 The association between PRES and tacrolimus and cyclosporine has been well described. Although sirolimus has been shown in vitro to induce astrocyte swelling identical to that observed with cyclosporine or tacrolimus, 8 this is the first report of PRES occurring in the setting of sirolimus treatment, in which sirolimus appears to be the causative agent. The patient described here had a rapid resolution of symptoms due to withdrawal of sirolimus and blood pressure control. Thus, in patients presenting with PRES and receiving treatment with sirolimus, substitution of sirolimus for another immunosuppressive agent should be strongly considered. 
